PRESS RELEASE published on 11/14/2024 at 19:00, 2 years ago Quarterly financial reporting / Third quarter financial report ABIONYX Pharma reports Q3 2024 revenue of €3.4m and cash position of €4.1m before IRIS Pharma's CIR receipt. General Meeting on November 28, 2024, at 2.00 pm CET Cash Position General Meeting Biotech Company ABIONYX Pharma Revenue Update
BRIEF published on 10/24/2024 at 19:35, 2 years ago ABIONYX Pharma presents the results of the RACERS study ABIONYX Pharma CER-001 Brain Fog Kidney Week Neuroinflammation
PRESS RELEASE published on 10/24/2024 at 19:30, 2 years ago Inside Information / Other news releases ABIONYX Pharma's RACERS study on CER-001 shows positive impact on cognitive impairment in brain-fog patients, presenting new clinical results at ASN 2024 Annual Meeting. Potential treatment for neuroinflammation ABIONYX Pharma CER-001 Brain-fog Neuroinflammation RACERS Study
BRIEF published on 10/21/2024 at 20:05, 2 years ago ABIONYX Pharma receives positive EMA opinion for CER-001 ABIONYX Pharma CER-001 EMA AMM LCAT Deficiency
PRESS RELEASE published on 10/21/2024 at 20:00, 2 years ago Inside Information / Other news releases ABIONYX Pharma receives positive feedback from EMA for CER-001 in LCAT Deficiency, allowing submission of data from 2 prospective process validation batches for MAA manufacturing ABIONYX Pharma CER-001 EMA LCAT Deficiency Process Validation Batches
BRIEF published on 08/22/2024 at 18:05, 2 years 2 months ago ABIONYX Pharma: Review of the first half of 2024 Biotechnology Fundraising Treasury Turnover ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 2 years 2 months ago Inside Information / Other news releases ABIONYX Pharma reports €2.4m sales and €5.3m cash position for H1 2024, focused on innovative therapies. Raised €3.4m for sepsis program in the US Sales Cash Position Innovative Therapies ABIONYX Pharma Sepsis
BRIEF published on 07/01/2024 at 09:27, 2 years 4 months ago ABIONYX Successfully Completes €3.4 Million Capital Increase Capital Increase Biotech Shares And Warrants ABIONYX Sepsis Development
PRESS RELEASE published on 07/01/2024 at 09:22, 2 years 4 months ago Inside Information / Other news releases ABIONYX successfully completes a capital increase of c.€3.4 million through the issuance of shares with warrants. The fundraising aims to strengthen the company's cash position for its development in sepsis and the United States Fundraising Capital Increase Sepsis ABIONYX Shares With Warrants
BRIEF published on 06/27/2024 at 19:27, 2 years 4 months ago ABIONYX Pharma Achieves Unanimous Approval at Combined General Meeting Shareholders Biotech General Meeting Resolutions ABIONYX Pharma
Published on 11/16/2026 at 00:00, 44 minutes ago Redwood AI Plans to Develop Canadian and U.S. Defence Compliance Capabilities for its Post-Quantum Cybersecurity Platform
Published on 11/14/2026 at 12:56, 1 day 11 hours ago Gabriel Announces Dismissal of ICSID Annulment Application
Published on 11/14/2026 at 01:30, 1 day 23 hours ago NuRAN Wireless Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published on 11/14/2026 at 00:40, 2 days ago BEACN Announces Annual General and Special Meeting Results
Published on 11/14/2026 at 00:35, 2 days ago American Hotel Income Properties REIT LP Reports Q3 2026 Results
Published on 11/13/2026 at 23:24, 2 days 1 hour ago EQS-Adhoc: ASOS PLC: Repurchase of £90m of 2028 Convertible Bonds
Published on 11/13/2026 at 21:52, 2 days 2 hours ago EQS-Adhoc: Airbus reports share buyback transactions 9-13 November 2026
Published on 11/13/2026 at 19:08, 2 days 5 hours ago EQS-Adhoc: CHAPTERS Group AG: Successful Completion of Private Placement of the Capital Increase from Authorized Capital Resolved on November 13, 2026
Published on 11/13/2026 at 18:04, 2 days 6 hours ago EQS-Adhoc: CHAPTERS Group AG: Capital Increase from Authorized Capital Resolved
Published on 11/13/2026 at 11:35, 2 days 13 hours ago ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/12/2026 at 23:12, 3 days 1 hour ago Belgrano continues the implementation of its public share buyback offer (OPRA)
Published on 11/12/2026 at 18:36, 3 days 6 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/10/2026
Published on 11/12/2026 at 18:00, 3 days 6 hours ago Information concerning the total number of voting rights and shares in the share capital as of November 12, 2026
Published on 11/12/2026 at 17:40, 3 days 7 hours ago Financial information for the period ended 30 September 2026
